Based on ratings from 7 stock analysts, the Sabra Health Care REIT Inc stock price is expected to increase by 18.76% in 12 months. This is calculated by using the average 12-month stock price forecast for Sabra Health Care REIT Inc. The lowest target is $14.00 and the highest is $21.00. Please note analyst price targets are not guaranteed and could be missed completely.
Sabra Health Care REIT Inc has a total of 7 Wall St Analyst ratings. There are 4 buy ratings, 3 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Sabra Health Care REIT Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
omotayo okusanya Deutsche Bank | Buy | $21.0 | initiatedcoverage | Jan 29, 2024 |
vikram malhotra Mizuho Securities | Buy | $17.0 | maintained | Jan 3, 2024 |
richard anderson Wedbush | Buy | $17.0 | maintained | Jan 2, 2024 |
michael lewis Truist Financial | Buy | $15.0 | maintained | Dec 26, 2023 |
steve manaker Stifel Nicolaus | Buy | $16.0 | maintained | Nov 7, 2023 |
joshua dennerlein Bank of America Securities | Buy | None | maintained | Oct 20, 2023 |
joe dickstein Jefferies | Buy | $15.0 | upgraded | Sep 20, 2023 |
michael r lewis Truist Financial | Buy | $13.0 | maintained | Mar 29, 2023 |
amanda sweitzer Robert W. Baird | Buy | $18.0 | maintained | Nov 3, 2021 |
john kim BMO Capital | Buy | $21.0 | upgraded | May 21, 2021 |
joseph france Loop Capital Markets | Buy | $25.0 | reiterated | Nov 6, 2018 |
peter martin JMP Securities | Buy | $23.0 | upgraded | Sep 5, 2017 |
joshua raskin Nephron | Buy | $28.0 | maintained | Feb 24, 2017 |
daniel altscher B.Riley Financial | Buy | $24.0 | reiterated | Feb 23, 2016 |
michael carroll RBC Capital | Buy | $33.0 | rated | Jan 27, 2014 |
brian tanquilut Jefferies | Buy | $11.0 | rated | May 25, 2010 |
jason gurda KeyBanc | Buy | None | upgraded | Jun 16, 2009 |
gary taylor Cowen & Co. | Buy | None | upgraded | Jan 27, 2009 |
In 2023, SBRA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SBRA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
SOFI-USD
$8.33
TMUS-USD
$161.76
TXN-USD
$162.4
UPST-USD
$33.9
$27.88
TXG-USD
$49.11